In the late 1970s it was discovered that the brains of patients with Alzheimer's disease were
deficient in acetylcholine, 4 one of the main neurotransmitters of the central nervous system …

Alzheimer s disease (AD) is the most common cause of dementia in the elderly (1). The
prevalence of AD at the age of 65 is approximately 10% and approaches 50% by the age of …

Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory and
cognitive loss, and represents the leading cause of dementia in elderly people. Besides the …

Since the 1980s, the cholinergic hypothesis of the pathogenesis of Alzheimer's disease has
proven to be a strong stimulus to pharmacological strategies aimed at correcting the …

The cholinergic hypothesis claims that a decrease of acetylcholine (ACh) in the brain of
patients with Alzheimer's Disease (AD) plays an important role in the deterioration of …

Alzheimer's disease (AD) is the leading cause of dementia in mid-to-late life, and is
estimated to afflict approximately 20 million people worldwide. There are considerable …

The systematic development of Alzheimer Disease (AD) therapy is only ten year old. It was
initiated on a large scale following the publication in New England Journal of Medicine of …

Since the identification of the cholinergic deficit, strategies aimed at enhancing cholinergic
neurotransmission have dominated the field of pharmacology in Alzheimer's disease (AD) …

Alzheimer's disease is the most prevalent late-onset neurodegenerative disorder of
unknown origin. The cholinergic hypothesis of Alzheimer's disease attributes the cognitive …

Deficits in cholinergic function contribute to the pathology of Alzheimer's disease (AD),
affecting cognition, behaviour and activities of daily living. Pharmacological intervention …